Decrease in naturally occurring antibodies against epitopes of Alzheimer’s disease (AD) risk gene products is associated with cognitive decline in AD

Table 3 Assessment of diagnostic utility of NAbs of “total” panels by ROC analysis

NO	NAbs	CN vs. AD			CN vs. MCI
NO	NAbs	AUC (95% CI)	Cutoff	Sensitivity^{against 95% specificity}	AUC (95% CI)	Cutoff	Sensitivity^{against 95% specificity}
1	ADAM10	0.722 (0.629–0.816)	0.118	0.259	NA	NA	NA
2	ADAMTS1	0.686 (0.587–0.785)	0.128	0.111	NA	NA	NA
3	CLU	0.731 (0.639–0.823)	0.126	0.259	NA	NA	NA
4	FERMT2	0.724 (0.631–0.817)	0.182	0.278	NA	NA	NA
5	NDUFAF6	0.662 (0.562–0.763)	0.185	0.204	NA	NA	NA
6	OARD1	0.694 (0.596–0.791)	0.113	0.185	NA	NA	NA
7	PTK2B	0.730 (0.637–0.824)	0.125	0.333	NA	NA	NA
8	SLC24A4	0.715 (0.62–0.809)	0.145	0.333	NA	NA	NA
9	SORL1	0.760 (0.671–0.849)	0.149	0.296	0.842 (0.734–0.949)	0.148	0.500
10	SPPL2A	0.683 (0.585–0.781)	0.151	0.241	0.938 (0.876–0.999)	0.150	0.750
11	TREM2	0.806 (0.727–0.884)	0.164	0.370	0.834 (0.735–0.934)	0.164	0.188
12	WWOX	0.709 (0.614–0.804)	0.148	0.333	0.814 (0.711–0.916)	0.146	0.188
13	ADAMTS4	0.673 (0.574–0.773)	0.135	0.259	NA	NA	NA
14	SPRED2	0.748 (0.658–0.837)	0.202	0.333	0.856 (0.765–0.947)	0.202	0.563
15	TMEM163	0.751 (0.662–0.84)	0.149	0.333	0.910 (0.836–0.983)	0.149	0.563
16	TSPAN14	0.725 (0.632–0.818)	0.169	0.370	0.884 (0.797–0.970)	0.166	0.563
17	VKORC1	0.796 (0.715–0.877)	0.178	0.352	0.952 (0.895–1.000)	0.178	0.813

NAbs natural antibodies, AD Alzheimer’s disease, MCI mild cognitive impairment, CN cognitively normal controls, NA not applicable, ROC receiver operating characteristic, AUC area under the curve

ISSN: 1742-2094